Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

ClinicalTrials.gov ID: NCT01233960

Public ClinicalTrials.gov record NCT01233960. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease

Study identification

NCT ID
NCT01233960
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Mesoblast, Inc.
Industry
Enrollment
73 participants

Conditions and interventions

Interventions

  • Prochymal® Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 28, 2010
Primary completion
Sep 14, 2014
Completion
Sep 14, 2014
Last update posted
Mar 10, 2026

2010 – 2014

United States locations

U.S. sites
16
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
University of California, San Francisco San Francisco California 94115
Clinical Research of West Florida Clearwater Florida 33765
Shafran Gastroenterology Center Winter Park Florida 32789
University of Chicago Chicago Illinois 60611
Cotton-O'Neil Clinical Research Center Topeka Kansas 66606
University of Maryland, Baltimore Baltimore Maryland 21201
Chevy Chase Clinical Research Chevy Chase Maryland 20815
Saint Louis Center for Clinical Research St Louis Missouri 63128
St. Louis Center for Clinical Studies St Louis Missouri 63128
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756
Weill Cornell Medical College New York New York 10028
Mount Sinai School of Medicine New York New York 10029
Gastroenterology Center of the Midsouth, PC Germantown Tennessee 38138
Vanderbilt University Medical Center Nashville Tennessee 37232
Baylor University Medical Center Dallas Texas 75246
McGuire Research Institute Richmond Virginia 23249

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01233960, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 10, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01233960 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →